Your browser is no longer supported. Please, upgrade your browser.
ENOB Enochian Biosciences, Inc. monthly Stock Chart
ENOB [NASD]
Enochian Biosciences, Inc.
Index- P/E- EPS (ttm)-0.21 Insider Own22.60% Shs Outstand46.61M Perf Week-9.38%
Market Cap142.94M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float14.63M Perf Month-8.81%
Income-9.70M PEG- EPS next Q- Inst Own5.20% Short Float6.59% Perf Quarter-28.92%
Sales- P/S- EPS this Y48.60% Inst Trans-3.36% Short Ratio12.56 Perf Half Y-16.18%
Book/sh3.52 P/B0.82 EPS next Y- ROA-5.50% Target Price- Perf Year-50.09%
Cash/sh0.12 P/C23.82 EPS next 5Y- ROE-5.80% 52W Range1.95 - 13.43 Perf YTD-42.23%
Dividend- P/FCF- EPS past 5Y2.60% ROI- 52W High-78.41% Beta0.49
Dividend %- Quick Ratio7.30 Sales past 5Y- Gross Margin- 52W Low48.72% ATR0.18
Employees10 Current Ratio7.30 Sales Q/Q- Oper. Margin- RSI (14)35.69 Volatility7.36% 5.53%
OptionableNo Debt/Eq0.04 EPS Q/Q41.80% Profit Margin- Rel Volume0.98 Prev Close2.82
ShortableYes LT Debt/Eq0.04 Earnings- Payout- Avg Volume76.75K Price2.90
Recom- SMA20-6.22% SMA50-12.56% SMA200-18.74% Volume75,155 Change2.84%
Nov-01-20 09:35AM  
Sep-10-20 12:50AM  
Jul-27-20 08:00AM  
Jun-08-20 07:30AM  
May-14-20 09:50AM  
May-13-20 08:00AM  
Apr-23-20 07:00AM  
Apr-09-20 10:00AM  
Feb-24-20 07:30AM  
Feb-03-20 07:30AM  
Jan-06-20 07:30AM  
Dec-10-19 07:00AM  
Nov-25-19 07:00AM  
Nov-21-19 10:30AM  
Oct-31-19 04:17PM  
Oct-26-19 10:18AM  
Jun-03-19 07:00AM  
Apr-29-19 09:19AM  
Mar-07-19 12:45PM  
Feb-01-19 02:31PM  
Jan-16-19 04:00PM  
Jan-07-19 08:30AM  
Jan-04-19 08:00AM  
Dec-05-18 08:30AM  
Dec-03-18 08:30AM  
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-HB-01, a coopting Hepatitis B polymerase; ENOB-DC-01, an off-the-shelf DC vaccine pulsed with MCV lysate; ENOB-DC-11 innovative DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intratumoral injection. The company has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Center, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Enochian Biosciences, Inc. is headquartered in Los Angeles, California.